News
BioInnovation Institute & Science Prize for Innovation winners announced
BioInnovation Institute (BII), an international non-profit foundation…
Novo Holdings invests in US$105 million Series C Funding of Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech developing…
Destiny Pharma – Audited results for the year ended 31 December 2022
Exclusive North American partnering deal worth up to $570m plus…
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Data demonstrate that uPARAP is widely expressed at high…
Novo Holdings reports annual results
Copenhagen, Denmark – Novo Holdings today announced its financial…
Futura Medical Full Year Results for the year ended 31 December 2022
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
AMSilk Announces Extension of Series C Financing to EUR 54M
Funding enables AMSilk to accelerate industrial scale-up…
Destiny Pharma plc – Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration
Brighton, United Kingdom - 4 April 2023 - Destiny Pharma (AIM:…
Over DKK 3 billion (USD 413 million) raised by BioInnovation Institute portfolio companies to date
Portfolio company Adcendo Aps, today announces extension…
Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
Series A Financing extension led by Pontifax Venture Capital…
Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)
The global shortage of qualified health professionals is an increasing…
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext…
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases
Clinical candidate selection finalised for lead programme targeting…
Poolbeg Pharma Plc: Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned…
iOnctura Awarded UK’s MHRA Innovation Passport For Entry Into Innovative Licensing And Access Pathway (ILAP)
iOnctura, a clinical stage biotechnology company developing breakthrough…
Destiny Pharma – Landmark XF-73 Phase 2 data published in journal
Announces publication of XF-73 nasal gel Phase 2 data in leading…
Sequana Medical announces additional patents for DSR® in China and the United States
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext…
iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib
Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP…
Leucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre
Agreement to manufacture Leucid Lead asset, LEU011 for the…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
